CL2017001549A1 - Acido propanoico 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)util como inhibidores de kinunerina monooxigenasa - Google Patents
Acido propanoico 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)util como inhibidores de kinunerina monooxigenasaInfo
- Publication number
- CL2017001549A1 CL2017001549A1 CL2017001549A CL2017001549A CL2017001549A1 CL 2017001549 A1 CL2017001549 A1 CL 2017001549A1 CL 2017001549 A CL2017001549 A CL 2017001549A CL 2017001549 A CL2017001549 A CL 2017001549A CL 2017001549 A1 CL2017001549 A1 CL 2017001549A1
- Authority
- CL
- Chile
- Prior art keywords
- acute
- disease
- serious
- useful
- etilo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
<p>EL COMPUESTO DE FÓRMULA (1), EN LA QUE: R1 ES HETEROARILO NO SUSTITUIDO O SUSTITUIDO CON METILO, ETILO, HALO o =O; Y R2 ES H, METILO O ETILO; Y LAS SALES DEL MISMO SON INHIBIDORES DE KMO Y PUEDEN SER ÚTILES EN EL TRATAMIENTO DE DIVERSOS TRASTORNOS, POR EJEMPLO, PANCREATITIS AGUDA, ENFERMEDAD RENAL CRÓNICA, ENFERMEDAD RENAL AGUDA, LESIÓN RENAL AGUDA, OTROS ESTADOS PATOLÓGICOS ASOCIADOS CON SÍNDROME DE RESPUESTA INFLAMATORIA SISTÉMICA (SRIS), ENFERMEDAD DE HUNTINGTON, ENFERMEDAD DE ALZHEIMER, ATAXIAS ESPINOCEREBELOSAS, ENFERMEDAD DE PARKINSON, COMPLEJO SIDA-DEMENCIA, INFECCIÓN POR VIH, ESCLEROSIS LATERAL AMIOTRÓFICA (ELA), DEPRESIÓN, ESQUIZOFRENIA, SEPTICEMIA, CHOQUE CARDIOVASCULAR, TRAUMATISMO GRAVE, LESIÓN PULMONAR AGUDA, SÍNDROME DE DIFICULTAD RESPIRATORIA AGUDA, COLECISTITIS AGUDA, QUEMADURAS GRAVES, NEUMONÍA, PROCEDIMIENTOS QUIRÚRGICOS EXTENSOS, ISQUEMIA INTESTINAL, INSUFICIENCIA HEPÁTICA AGUDA GRAVE, ENCEFALOPATÍA HEPÁTICA AGUDA GRAVE O INSUFICIENCIA RENAL AGUDA.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422727 | 2014-12-19 | ||
| GBGB1508866.9A GB201508866D0 (en) | 2015-05-22 | 2015-05-22 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001549A1 true CL2017001549A1 (es) | 2018-01-26 |
Family
ID=54850210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001549A CL2017001549A1 (es) | 2014-12-19 | 2017-06-15 | Acido propanoico 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)util como inhibidores de kinunerina monooxigenasa |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9932328B2 (es) |
| EP (1) | EP3233844B1 (es) |
| JP (1) | JP6644790B2 (es) |
| KR (1) | KR102557791B1 (es) |
| CN (1) | CN107108594B (es) |
| AU (1) | AU2015367396C1 (es) |
| BR (1) | BR112017013193B1 (es) |
| CA (1) | CA2969385C (es) |
| CL (1) | CL2017001549A1 (es) |
| CO (1) | CO2017005872A2 (es) |
| CR (1) | CR20170261A (es) |
| DO (1) | DOP2017000141A (es) |
| EA (1) | EA033632B1 (es) |
| ES (1) | ES2737893T3 (es) |
| IL (1) | IL252155B (es) |
| JO (1) | JO3656B1 (es) |
| MX (1) | MX2017008069A (es) |
| NZ (1) | NZ732002A (es) |
| PE (1) | PE20171259A1 (es) |
| PH (1) | PH12017500993A1 (es) |
| SG (1) | SG11201703807VA (es) |
| TW (1) | TWI698433B (es) |
| UA (1) | UA120381C2 (es) |
| UY (1) | UY36451A (es) |
| WO (1) | WO2016097144A1 (es) |
| ZA (1) | ZA201702918B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA033632B1 (ru) * | 2014-12-19 | 2019-11-12 | Glaxosmithkline Ip Dev Ltd | 3-(6-АЛКОКСИ-5-ХЛОРБЕНЗО[d]ИЗОКСАЗОЛ-3-ИЛ)ПРОПИОНОВАЯ КИСЛОТА, ПОЛЕЗНАЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНУРЕНИНМОНООКСИГЕНАЗЫ |
| KR101684053B1 (ko) * | 2015-01-20 | 2016-12-08 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| US20100168192A1 (en) * | 2007-05-24 | 2010-07-01 | Neurosearch A/S | Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions |
| US20110230428A1 (en) * | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US8691824B2 (en) * | 2008-08-04 | 2014-04-08 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| CN102811620B (zh) * | 2010-01-25 | 2015-03-25 | Chdi基金会股份有限公司 | 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
| BR112014004845A2 (pt) * | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
| GB201322512D0 (en) | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EA033632B1 (ru) * | 2014-12-19 | 2019-11-12 | Glaxosmithkline Ip Dev Ltd | 3-(6-АЛКОКСИ-5-ХЛОРБЕНЗО[d]ИЗОКСАЗОЛ-3-ИЛ)ПРОПИОНОВАЯ КИСЛОТА, ПОЛЕЗНАЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНУРЕНИНМОНООКСИГЕНАЗЫ |
-
2015
- 2015-12-17 EA EA201791402A patent/EA033632B1/ru not_active IP Right Cessation
- 2015-12-17 JO JOP/2015/0324A patent/JO3656B1/ar active
- 2015-12-17 JP JP2017532625A patent/JP6644790B2/ja active Active
- 2015-12-17 PE PE2017001084A patent/PE20171259A1/es unknown
- 2015-12-17 EP EP15810681.5A patent/EP3233844B1/en active Active
- 2015-12-17 CN CN201580068887.0A patent/CN107108594B/zh active Active
- 2015-12-17 MX MX2017008069A patent/MX2017008069A/es active IP Right Grant
- 2015-12-17 AU AU2015367396A patent/AU2015367396C1/en active Active
- 2015-12-17 UA UAA201707042A patent/UA120381C2/uk unknown
- 2015-12-17 BR BR112017013193-5A patent/BR112017013193B1/pt active IP Right Grant
- 2015-12-17 NZ NZ732002A patent/NZ732002A/en unknown
- 2015-12-17 CA CA2969385A patent/CA2969385C/en active Active
- 2015-12-17 US US15/537,805 patent/US9932328B2/en active Active
- 2015-12-17 WO PCT/EP2015/080221 patent/WO2016097144A1/en active Application Filing
- 2015-12-17 UY UY0001036451A patent/UY36451A/es active IP Right Grant
- 2015-12-17 TW TW104142406A patent/TWI698433B/zh active
- 2015-12-17 KR KR1020177016276A patent/KR102557791B1/ko active IP Right Grant
- 2015-12-17 ES ES15810681T patent/ES2737893T3/es active Active
- 2015-12-17 SG SG11201703807VA patent/SG11201703807VA/en unknown
- 2015-12-17 CR CR20170261A patent/CR20170261A/es unknown
-
2017
- 2017-04-26 ZA ZA2017/02918A patent/ZA201702918B/en unknown
- 2017-05-08 IL IL252155A patent/IL252155B/en active IP Right Grant
- 2017-05-29 PH PH12017500993A patent/PH12017500993A1/en unknown
- 2017-06-14 DO DO2017000141A patent/DOP2017000141A/es unknown
- 2017-06-14 CO CONC2017/0005872A patent/CO2017005872A2/es unknown
- 2017-06-15 CL CL2017001549A patent/CL2017001549A1/es unknown
-
2018
- 2018-02-20 US US15/900,043 patent/US10273232B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990202A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 | |
| CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| EA201600589A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств | |
| BR112017009657A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
| NZ727392A (en) | Methods of preparing substituted nucleotide analogs | |
| EA201890641A3 (ru) | Стимуляторы sgc | |
| CL2017000866A1 (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos | |
| EA201691447A1 (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| EA201400990A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 | |
| GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
| EP4364743A3 (en) | A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | |
| BR112017006425A2 (pt) | derivado de isoxazol como inibidor de isocitrato desidrogenase 1 mutante | |
| MY183209A (en) | Heterocyclic compound | |
| CU20160155A7 (es) | Compuestos heteroaromáticos útiles como ligandos de dopamina d1 | |
| BR112017013130A2 (pt) | processo de fabricação de cenicriviroc e análogos relacionados | |
| BR112017019850A2 (pt) | ?processo melhorado para a preparação de apremilast? | |
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| CL2017001549A1 (es) | Acido propanoico 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)util como inhibidores de kinunerina monooxigenasa | |
| MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
| MA41782A (fr) | Traitement de patients atteints de diabète de type 2 | |
| DE112016001019A5 (de) | Maschinenanlage zur herstellung oder behandlung von synthetischen fäden | |
| BR112018008787A2 (pt) | solução aquosa de peróxido de hidrogênio compreendendo um estabilizante específico | |
| WO2016025494A3 (en) | Methods of monitoring adherence to quetiapine therapy | |
| EA201791456A1 (ru) | Пептиды-антагонисты cgrp |